Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-2-microglobulin as a tumor marker in solid malignancies.

M Lotzniker1, F Pavesi, L Marbello

  • 1Servizio Analisi Chimico-Cliniche, Policlinico S. Matteo, University of Pavia, Italia.

Oncology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).

Annals of hematology·2016
Same author

Development of simple equations for effective screening of spurious hemolysis in whole-blood specimens.

International journal of laboratory hematology·2014
Same author

Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia.

Heart, lung and vessels·2014
Same author

Influence of in vitro hemolysis on nucleated red blood cells and reticulocyte counts.

International journal of laboratory hematology·2012
Same author

Tetanus toxoid IgE may be useful in predicting allergy during childhood.

Journal of biological regulators and homeostatic agents·2012
Same author

The genomic and proteomic blueprint of mouse megakaryocytes derived from embryonic stem cells.

Journal of thrombosis and haemostasis : JTH·2012
Same journal

Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.

Oncology·2026
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
See all related articles

Beta-2-microglobulin (beta 2-MG) levels in cancer patients vary by stage and tumor markers like CEA. Lower beta 2-MG in advanced stages may indicate a reduced immune response or less differentiated cells.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Beta-2-microglobulin (beta 2-MG) is a protein found on the surface of most nucleated cells.
  • Its levels in serum can be affected by various conditions, including cancer.
  • Carcinogenic Embryonic Antigen (CEA) is another tumor marker used in cancer monitoring.

Purpose of the Study:

  • To investigate the relationship between serum beta-2-microglobulin (beta 2-MG) levels and cancer staging (TNM classification) and Carcinoembryonic Antigen (CEA) levels.
  • To explore the potential implications of beta 2-MG variations in different cancer stages and patient outcomes.

Main Methods:

  • Sera from 186 cancer patients were analyzed for beta-2-microglobulin (beta 2-MG) and Carcinoembryonic Antigen (CEA).
  • Patients were categorized into groups based on diagnosis stage (D-I to D-IV) and follow-up status (remission F-RS, relapse F-RP).

Related Experiment Videos

  • Serum creatinine and urea levels were confirmed to be normal in all patients.

    • Main Results:

    • Significantly lower beta 2-MG levels were observed in stage D-I compared to D-II and D-III (p < 0.01).
    • Stage D-IV beta 2-MG levels overlapped with D-I.
    • No significant difference in beta 2-MG was found between patients in remission (F-RS) and relapse (F-RP).
    • Patients with CEA > 100 ng/ml showed beta 2-MG levels similar to D-I and D-IV stages.
    • In 10% of stage IV patients or those with CEA > 100 ng/ml, beta 2-MG was below the healthy population mean.

    Conclusions:

    • Beta-2-microglobulin (beta 2-MG) production may be an nonspecific reaction to tumors.
    • Decreased beta 2-MG in advanced stages could suggest a diminished immunologic response.
    • Elevated serum beta 2-MG in early stages might indicate high cell turnover.
    • Low beta 2-MG in late stages could be due to weak protein expression by undifferentiated cells.